Skip to content
Peptidepedia

TB-500 Side Effects: Safety Profile, Risks & What to Expect (2026)

From Peptidepedia, the trusted peptide wiki.

Side Effects

TB-500 is generally considered well-tolerated based on available research and anecdotal reports. Thymosin beta-4 has demonstrated a favorable safety profile in clinical trials, with minimal reported adverse effects.

Commonly Reported:

  • Injection site reactions, including temporary redness, irritation, or mild discomfort
    • Note that these reactions are plausible based on medical understanding, but have not been demonstrated in human trials
  • Temporary fatigue or lethargy, particularly during initial use
    • Plausible but currently undemonstrated
  • Headaches (occasionally reported)

Potential Concerns: The relationship between thymosin beta-4 and cancer is genuinely contested in the literature. Some laboratory studies suggest it may promote the spread of certain cancers, while other studies have found that thymosin beta-4 inhibits tumor cell proliferation. No direct evidence links TB-500 use to cancer development in humans. Long-term safety data in humans remains limited, and the effects of extended use are not well characterized.

Frequently Asked Questions

Clinical trials of thymosin beta-4 have demonstrated that it is safe and well-tolerated at therapeutic doses in animals. However, long-term safety data specifically for TB-500 in humans is limited, and potential risks from unregulated products include contamination and inconsistent dosing.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Goldstein AL, Kleinman HK. Minireview: Crosstalk between thymosin β4 and the chemokine network. Ann N Y Acad Sci. 2015.
  2. Philp D, Kleinman HK. Animal studies with thymosin β4, a multifunctional tissue repair and regeneration peptide. Ann N Y Acad Sci. 2012.
  3. Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999.
  4. Smart N, et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007.
  5. RegeneRx Biopharmaceuticals. Phase II Clinical Trials: Thymosin Beta-4 for Dermal Wound Healing.
  6. World Anti-Doping Agency. The 2024 Prohibited List International Standard.
  7. Drip Hydration. The Wolverine Stack: Can BPC 157 and TB 500 Accelerate Injury Recovery?
  8. Examine.com. Thymosin Beta-4 Research Breakdown.
  9. U.S. Food and Drug Administration. Bulk Drug Substances Under Evaluation for Use in Compounding Under Section 503A.
←Read the full TB-500 guide

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”